

Erwin F Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1375718/publications.pdf>

Version: 2024-02-01

77
papers

14,225
citations

53794

45
h-index

74163

75
g-index

80
all docs

80
docs citations

80
times ranked

21963
citing authors

#	ARTICLE	IF	CITATIONS
1	TPL-2 Inhibits IFN- γ Expression via an ERK1/2-TCF-FOS Axis in TLR4-Stimulated Macrophages. <i>Journal of Immunology</i> , 2022, 208, 941-954.	0.8	3
2	An immune-sympathetic neuron communication axis guides adipose tissue browning in cancer-associated cachexia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	28
3	Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1400-1408.	0.9	11
4	In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. <i>Oncogene</i> , 2021, 40, 2437-2447.	5.9	21
5	Psoriatic skin inflammation is promoted by c-Jun/AP-1-dependent CCL2 and IL-23 expression in dendritic cells. <i>EMBO Molecular Medicine</i> , 2021, 13, e12409.	6.9	42
6	The AP-1 transcription factors c-Jun and JunB are essential for CD8 $^{+}$ conventional dendritic cell identity. <i>Cell Death and Differentiation</i> , 2021, 28, 2404-2420.	11.2	18
7	Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model. <i>Experimental Dermatology</i> , 2021, 30, 1662-1674.	2.9	16
8	JunB is a key regulator of multiple myeloma bone marrow angiogenesis. <i>Leukemia</i> , 2021, 35, 3509-3525.	7.2	19
9	Calprotectin: from biomarker to biological function. <i>Gut</i> , 2021, 70, 1978-1988.	12.1	163
10	Sequestosome 1/p62 enhances chronic skin inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2386-2393.e4.	2.9	10
11	Syndecan-1 shedding by meprin β impairs keratinocyte adhesion and differentiation in hyperkeratosis. <i>Matrix Biology</i> , 2021, 102, 37-69.	3.6	6
12	Targeting AP-1 transcription factors by CRISPR in the prostate. <i>Oncotarget</i> , 2021, 12, 1956-1961.	1.8	11
13	Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment. <i>Cancer Research</i> , 2021, 81, 968-985.	0.9	27
14	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity. <i>Blood</i> , 2021, 138, 2644-2644.	1.4	0
15	Wnt signaling and Loxl2 promote aggressive osteosarcoma. <i>Cell Research</i> , 2020, 30, 885-901.	12.0	68
16	Cutaneous Immune Cell-Microbiota Interactions Are Controlled by Epidermal JunB/AP-1. <i>Cell Reports</i> , 2019, 29, 844-859.e3.	6.4	13
17	Role of bulge epidermal stem cells and <sc>TSLP</sc> signaling in psoriasis. <i>EMBO Molecular Medicine</i> , 2019, 11, e10697.	6.9	17
18	Fra-2 $^{+}$ expressing macrophages promote lung fibrosis. <i>Journal of Clinical Investigation</i> , 2019, 129, 3293-3309.	8.2	67

#	ARTICLE	IF	CITATIONS
19	Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. Blood, 2019, 134, 4341-4341.	1.4	0
20	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy. Blood, 2019, 134, 4415-4415.	1.4	0
21	Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration. Journal of Visualized Experiments, 2018, , .	0.3	8
22	EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO Molecular Medicine, 2018, 10, .	6.9	24
23	Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. Journal of Experimental Medicine, 2017, 214, 1387-1409.	8.5	80
24	Chronic systemic inflammation originating from epithelial tissues. FEBS Journal, 2017, 284, 505-516.	4.7	19
25	Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes and Development, 2016, 30, 489-501.	5.9	239
26	Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Science Translational Medicine, 2016, 8, 330ra37.	12.4	133
27	Role of IL-17A signalling in psoriasis and associated bone loss. Clinical and Experimental Rheumatology, 2016, 34, 17-20.	0.8	23
28	A waste of insulin interference. Nature, 2015, 521, 430-431.	27.8	34
29	Signalling in inflammatory skin disease by AP-1 (Fos/Jun). Clinical and Experimental Rheumatology, 2015, 33, S44-9.	0.8	25
30	Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17582-17587.	7.1	45
31	Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Molecular Medicine, 2014, 6, 1312-1327.	6.9	92
32	Targeting <i>miR-21</i> to Treat Psoriasis. Science Translational Medicine, 2014, 6, 225re1.	12.4	123
33	Regulation of Steatohepatitis and PPAR ^{Î³} Signaling by Distinct AP-1 Dimers. Cell Metabolism, 2014, 19, 84-95.	16.2	99
34	Inhibition of De Novo NAD + Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage. Cancer Cell, 2014, 26, 826-839.	16.8	162
35	A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Cell Metabolism, 2014, 20, 433-447.	16.2	535
36	Activator protein 1 transcription factor fos-related antigen 1 (fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology, 2014, 59, 261-273.	7.3	25

#	ARTICLE	IF	CITATIONS
37	Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos. <i>Genes and Development</i> , 2013, 27, 1959-1973.	5.9	53
38	S100A8-S100A9 Protein Complex Mediates Psoriasis by Regulating the Expression of Complement Factor C3. <i>Immunity</i> , 2013, 39, 1171-1181.	14.3	205
39	Mouse models for liver cancer. <i>Molecular Oncology</i> , 2013, 7, 206-223.	4.6	144
40	JUNB/AP-1 controls IFN- β during inflammatory liver disease. <i>Journal of Clinical Investigation</i> , 2013, 123, 5258-5268.	8.2	44
41	A Validated Regulatory Network for Th17 Cell Specification. <i>Cell</i> , 2012, 151, 289-303.	28.9	1,010
42	Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. <i>Nature Cell Biology</i> , 2012, 14, 1203-1211.	10.3	218
43	Psoriasis: what we have learned from mouse models. <i>Nature Reviews Rheumatology</i> , 2010, 6, 704-714.	8.0	190
44	Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 21264-21269.	7.1	135
45	Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20423-20428.	7.1	58
46	Signal integration by JNK and p38 MAPK pathways in cancer development. <i>Nature Reviews Cancer</i> , 2009, 9, 537-549.	28.4	2,122
47	Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. <i>Nature Cell Biology</i> , 2008, 10, 1003-1011.	10.3	41
48	c-Jun Controls Histone Modifications, NF- κ B Recruitment, and RNA Polymerase II Function To Activate the <i>ccl2</i> Gene. <i>Molecular and Cellular Biology</i> , 2008, 28, 4407-4423.	2.3	83
49	Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10525-10530.	7.1	163
50	Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17105-17110.	7.1	64
51	NF- κ B p50 and p52 Regulate Receptor Activator of NF- κ B Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1. <i>Journal of Biological Chemistry</i> , 2007, 282, 18245-18253.	3.4	364
52	Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation. <i>Bone</i> , 2007, 40, 867-875.	2.9	26
53	Simultaneous generation of <i>fra</i> ^{-/-} conditional and <i>fra</i> ^{-/-} knock-out mice. <i>Genesis</i> , 2007, 45, 447-451.	1.6	23
54	p38 β suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. <i>Nature Genetics</i> , 2007, 39, 741-749.	21.4	342

#	ARTICLE	IF	CITATIONS
55	Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. International Journal of Biochemistry and Cell Biology, 2006, 38, 1043-1049.	2.8	131
56	Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature, 2005, 437, 369-375.	27.8	538
57	Fos and Jun Proteins Are Specifically Expressed During Differentiation of Human Keratinocytes. Journal of Investigative Dermatology, 2005, 124, 212-220.	0.7	109
58	Fos/AP-1 proteins in bone and the immune system. Immunological Reviews, 2005, 208, 126-140.	6.0	457
59	Essential role of RSK2 in c-Fos-dependent osteosarcoma development. Journal of Clinical Investigation, 2005, 115, 664-672.	8.2	81
60	Essential role of RSK2 in c-Fos-dependent osteosarcoma development. Journal of Clinical Investigation, 2005, 115, 664-672.	8.2	45
61	Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. Journal of Cell Biology, 2004, 164, 613-623.	5.2	188
62	JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells. Cell, 2004, 119, 431-443.	28.9	384
63	Rhabdomyosarcoma development in mice lacking Trp53 and Fos. Cancer Cell, 2003, 4, 477-482.	16.8	68
64	AP-1: a double-edged sword in tumorigenesis. Nature Reviews Cancer, 2003, 3, 859-868.	28.4	1,867
65	Liver Tumor Development. Cell, 2003, 112, 181-192.	28.9	445
66	Impaired Long-Term Memory and NR2A-Type NMDA Receptor-Dependent Synaptic Plasticity in Mice Lacking c-Fos in the CNS. Journal of Neuroscience, 2003, 23, 9116-9122.	3.6	321
67	Promoter Specificity and Biological Activity of Tethered AP-1 Dimers. Molecular and Cellular Biology, 2002, 22, 4952-4964.	2.3	171
68	Fra-1 substitutes for c-Fos in AP-1-mediated signal transduction in retinal apoptosis. Journal of Neurochemistry, 2002, 80, 1089-1094.	3.9	27
69	JunB can substitute for Jun in mouse development and cell proliferation. Nature Genetics, 2002, 30, 158-166.	21.4	132
70	Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO Journal, 2002, 21, 1782-1790.	7.8	234
71	Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage. Cell, 2001, 104, 21-32.	28.9	215
72	C-Jun N-terminal Kinase (Jnk)1 and Jnk2 Have Similar and Stage-Dependent Roles in Regulating T Cell Apoptosis and Proliferation. Journal of Experimental Medicine, 2001, 193, 317-328.	8.5	199

#	ARTICLE	IF	CITATIONS
73	Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis. Journal of Experimental Medicine, 2001, 193, 353-364.	8.5	59
74	Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nature Genetics, 2000, 24, 184-187.	21.4	447
75	Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nature Medicine, 1999, 5, 314-319.	30.7	348
76	JunB is essential for mammalian placentation. EMBO Journal, 1999, 18, 934-948.	7.8	232
77	Stable murine chondrogenic cell lines derived from c- <i>fos</i> -induced cartilage tumors. Journal of Bone and Mineral Research, 1993, 8, 839-847.	2.8	35